novo nordisk semaglutide nash Nordisk's misses the mark in study Novo's trial of weight-loss drug

Description

Glucagon receptor agonists carry a theoretical (though unconfirmed in humans) thyroid C-cell concern

Perioperative Management and Potential Drug Discontinuation to Avoid Aspiration Pneumonia GLP-1 RAs are increasingly used in patients undergoing elective or urgent surgeries, including facial and body plastic surgery

Surgery remains possible, but expect a short pre-op plan: Denver Health accepts up to BMI 65 but requests a five-to-ten percent weight loss to shrink the liver

These include brief stinging during injection lasting seconds to a minute, small drop of blood at the injection site, temporary redness in a quarter-sized area around the site, slight firmness or bump at the injection location, mild warmth at the site for several hours, and faint bruising that appears over the following day